The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict CVS Caremark's revenues will grow 1.4% and EPS will grow 18.5%.
The average estimate for revenue is $31.14 billion. On the bottom line, the average EPS estimate is $0.96.
Last quarter, CVS Caremark reported revenue of $30.76 billion. GAAP reported sales were 0.1% lower than the prior-year quarter's $30.80 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at $0.83. GAAP EPS of $0.77 for Q1 were 31% higher than the prior-year quarter's $0.59 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 18.1%, 150 basis points better than the prior-year quarter. Operating margin was 5.5%, 90 basis points better than the prior-year quarter. Net margin was 3.1%, 60 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $125.69 billion. The average EPS estimate is $3.98.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,700 members out of 1,766 rating the stock outperform, and 66 members rating it underperform. Among 458 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 450 give CVS Caremark a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on CVS Caremark is outperform, with an average price target of $58.17.
Is CVS Caremark the right retailer for your portfolio? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average retailing powerhouse. Click here for instant access to this free report.
- Add CVS Caremark to My Watchlist.